Literature DB >> 34049973

Epigenetic Induction of Mitochondrial Fission Is Required for Maintenance of Liver Cancer-Initiating Cells.

Miaoling Tang1, Meisongzhu Yang2, Geyan Wu1, Shuang Mo2, Xingui Wu2, Shuxia Zhang2, Ruyuan Yu2, Yameng Hu2, Yingru Xu2, Ziwen Li2, Xinyi Liao2, Jun Li3, Libing Song4.   

Abstract

Mitochondrial dynamics play vital roles in the tumorigenicity and malignancy of various types of cancers by promoting the tumor-initiating potential of cancer cells, suggesting that targeting crucial factors that drive mitochondrial dynamics may lead to promising anticancer therapies. In the current study, we report that overexpression of mitochondrial fission factor (MFF), which is upregulated significantly in liver cancer-initiating cells (LCIC), promotes mitochondrial fission and enhances stemness and tumor-initiating capability in non-LCICs. MFF-induced mitochondrial fission evoked mitophagy and asymmetric stem cell division and promoted a metabolic shift from oxidative phosphorylation to glycolysis that decreased mitochondrial reactive oxygen species (ROS) production, which prevented ROS-mediated degradation of the pluripotency transcription factor OCT4. CRISPR affinity purification in situ of regulatory elements showed that T-box transcription factor 19 (TBX19), which is overexpressed uniquely in LCICs compared with non-LCICs and liver progenitor cells, forms a complex with PRMT1 on the MFF promoter in LCICs, eliciting epigenetic histone H4R3me2a/H3K9ac-mediated transactivation of MFF. Targeting PRMT1 using furamidine, a selective pharmacologic inhibitor, suppressed TBX19-induced mitochondrial fission, leading to a profound loss of self-renewal potential and tumor-initiating capacity of LCICs. These findings unveil a novel mechanism underlying mitochondrial fission-mediated cancer stemness and suggest that regulation of mitochondrial fission via inhibition of PRMT1 may be an attractive therapeutic option for liver cancer treatment. SIGNIFICANCE: These findings show that TBX19/PRMT1 complex-mediated upregulation of MFF promotes mitochondrial fission and tumor-initiating capacity in liver cancer cells, identifying PRMT1 as a viable therapeutic target in liver cancer. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34049973     DOI: 10.1158/0008-5472.CAN-21-0436

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  T-box transcription factor 19 promotes hepatocellular carcinoma metastasis through upregulating EGFR and RAC1.

Authors:  Xiaoyu Ji; Xiaoping Chen; Bixiang Zhang; Meng Xie; Tongyue Zhang; Xiangyuan Luo; Danfei Liu; Yangyang Feng; Yijun Wang; Mengyu Sun; Congxin Li; Wenjie Huang; Limin Xia
Journal:  Oncogene       Date:  2022-02-26       Impact factor: 9.867

2.  Super-Resolution Quantification of T2DM-Induced Mitochondrial Morphology Changes and Their Implications in Pharmacodynamics of Metformin and Sorafenib.

Authors:  Yang Du; Ya-Juan Zhu; Bo Zeng; Xiao-Li Mu; Ji-Yan Liu
Journal:  Front Pharmacol       Date:  2022-07-06       Impact factor: 5.988

3.  HAX1 maintains the glioma progression in hypoxia through promoting mitochondrial fission.

Authors:  Jinghui Lin; Yang Wang; Zhiqing Lin
Journal:  J Cell Mol Med       Date:  2021-11-10       Impact factor: 5.310

4.  Ubiquilin 1 suppresses the cancer stem cell-like traits of non-small cell lung cancer cells by regulating reactive oxygen species homeostasis.

Authors:  Ting Liu; Qianqian Ma; Wenjie Li; Yan Hu; Jun Yang; Qi Yao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 5.  Mechanism of cancer stemness maintenance in human liver cancer.

Authors:  Ning Liang; Tao Yang; Qian Huang; Pengfei Yu; Chaoxu Liu; Liusheng Chen; Qian Wang; Gang Wang; Xianli He
Journal:  Cell Death Dis       Date:  2022-04-21       Impact factor: 9.685

Review 6.  Targeted Mitochondrial Epigenetics: A New Direction in Alzheimer's Disease Treatment.

Authors:  Ying Song; Xin-Yi Zhu; Xiao-Min Zhang; He Xiong
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.